Viking Therapeutics Inc Quick Ratio (VKTX) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Viking Therapeutics Inc   (NASDAQ: VKTX)

Viking Therapeutics Inc 's Quick Ratio

VKTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Viking Therapeutics Inc 's Cash & cash equivalent grew by 91.33 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Viking Therapeutics Inc 's Quick Ratio to 7.17, Quick Ratio remained below Viking Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 194 other companies have achieved higher Quick Ratio than Viking Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 591 to 749.

Explain Quick Ratio?
How much Cash & cash equivalents VKTX´s has?
What are VKTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VKTX Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3
Y / Y Current Liabilities Change 422.42 % 247.98 % 457.4 % 184.24 % 1.69 %
Y / Y Cash & cash equivalent Change 34.32 % -37.89 % -29.22 % -21.81 % -23.2 %
Quick Ratio MRQ 7.17 4.57 5.67 9.22 27.88
VKTX's Total Ranking # 749 # 591 # 346 # 95 #
Seq. Current Liabilities Change 22.11 % 3.13 % 38.93 % 198.6 % -18.67 %
Seq. Cash & cash equivalent Change 91.33 % -16.8 % -14.56 % -1.24 % -11.53 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 195
Healthcare Sector # 321
Overall Market # 749


Quick Ratio Statistics
High Average Low
66.27 21.53 0.12
(Dec 31 2018)   (Mar 31 2015)




Financial Statements
Viking Therapeutics Inc 's Current Liabilities $ 134 Millions Visit VKTX's Balance sheet
Viking Therapeutics Inc 's Cash & cash equivalent $ 960 Millions Visit VKTX's Balance sheet
Source of VKTX's Sales Visit VKTX's Sales by Geography


Cumulative Viking Therapeutics Inc 's Quick Ratio

VKTX's Quick Ratio for the trailling 12 Months

VKTX Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 313.42 % 209.73 % 150.09 % 39.71 % 1.9 %
Y / Y Cash & cash equivalent TTM Growth -15.46 % -27.71 % -21.95 % -17.61 % 2.47 %
Quick Ratio TTM 6.5 7.94 11.8 20.16 31.77
Total Ranking TTM # 3501 # 2497 # 2234 # 2060 #
Seq. Current Liabilities TTM Growth 34.03 % 32.56 % 57.12 % 48.1 % 0.41 %
Seq. Cash & cash equivalent TTM Growth 9.71 % -10.81 % -8.08 % -6.01 % -6.18 %

Quick ratio ranking by company, industry and sector >> Back to VKTX Financial Strength Comparisons >> Go to Compare VKTX Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2026 to $133.90 millions, cumulative Quick Ratio decreased to 6.5 below the Viking Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 420 other companies have achieved higher Quick Ratio than Viking Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2497 to 3501.

Explain Quick Ratio?
How much Cash & cash equivalents VKTX´s has?
What are VKTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 421
Healthcare Sector # 857
Within the Market # 3501


trailing twelve months Quick Ratio Statistics
High Average Low
60.34 21.44 1.33
(Jun 30 2019)   (Dec 31 2015)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Telomir Pharmaceuticals Inc   19.07 $ 4.516  Millions$ 0.237  Millions
Onkure Therapeutics Inc   18.58 $ 163.305  Millions$ 8.789  Millions
Keros Therapeutics Inc   16.36 $ 259.464  Millions$ 15.858  Millions
Design Therapeutics Inc   16.36 $ 208.608  Millions$ 12.753  Millions
Avalo Therapeutics Inc   15.63 $ 392.966  Millions$ 25.135  Millions
Bioage Labs Inc   14.91 $ 283.637  Millions$ 19.027  Millions
Damora Therapeutics Inc   14.72 $ 528.478  Millions$ 35.892  Millions
Protagonist Therapeutics inc   14.42 $ 800.064  Millions$ 55.464  Millions
Stablecoin Development Corporation  13.01 $ 7.153  Millions$ 0.550  Millions
Uniqure N v   12.78 $ 768.430  Millions$ 60.142  Millions
Rhythm Pharmaceuticals Inc   12.62 $ 320.944  Millions$ 25.438  Millions
Dyne Therapeutics Inc   12.53 $ 1,134.386  Millions$ 90.545  Millions
Sensei Biotherapeutics Inc   12.44 $ 174.795  Millions$ 14.049  Millions
Spyre Therapeutics Inc   12.24 $ 82.727  Millions$ 6.760  Millions
Edgewise Therapeutics inc   12.10 $ 1,743.893  Millions$ 144.106  Millions
Newamsterdam Pharma Company N v   10.99 $ 628.242  Millions$ 57.154  Millions
Vtv Therapeutics Inc   10.99 $ 77.164  Millions$ 7.024  Millions
Cogent Biosciences Inc   10.82 $ 791.134  Millions$ 73.118  Millions
Bicycle Therapeutics Plc  10.57 $ 469.928  Millions$ 44.459  Millions
Lipocine Inc   10.55 $ 21.455  Millions$ 2.034  Millions
Adicet Bio Inc   10.28 $ 174.779  Millions$ 16.996  Millions
Nuvectis Pharma inc   9.91 $ 140.707  Millions$ 14.193  Millions
Renovorx Inc   9.76 $ 20.404  Millions$ 2.091  Millions
Aprea Therapeutics Inc   9.52 $ 37.846  Millions$ 3.975  Millions
Ideaya Biosciences Inc   8.70 $ 838.541  Millions$ 96.405  Millions
First Tracks Biotherapeutics Inc   8.60 $ 155.627  Millions$ 18.090  Millions
Arvinas Inc   7.98 $ 558.400  Millions$ 70.000  Millions
Wave Life Sciences Ltd   7.87 $ 431.012  Millions$ 54.760  Millions
Viking Therapeutics Inc   7.17 $ 959.813  Millions$ 133.897  Millions
Lb Pharmaceuticals Inc  7.03 $ 215.075  Millions$ 30.573  Millions

Date modified: 2026-10-30T13:26:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.